Floatz logo

Obinutuzumab

Plasmablastic Lymphoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Plasmablastic Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2BB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB

View all 26 →

Same molecule, other indications

Obinutuzumab is also rated in:

Richter transformationDormant
BB
Indicative ·
71 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →